Overcoming tumor-mediated immunosuppression

Immunotherapy

Volumn 6, Issue 9, 2014, Pages 973-988

  Schlößer, Hans Anton ^a   Theurich, Sebastian ^a   Shimabukuro Vornhagen, Alexander ^a   Holtick, Udo ^a   Stippel, Dirk Ludger ^a   Von Bergwelt Baildon, Michael ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

cancer; checkpoint inhibitors; CTLA 4; immune escape; immunotherapy; PD 1; PD L1; tumor mediated immunosuppression

Indexed keywords

CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; TUMOR ANTIGEN;

ANTIGEN RECOGNITION; APOPTOSIS; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CELL FUNCTION; CELL STIMULATION; EFFECTOR CELL; GENE EXPRESSION; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNE SYSTEM; MYELOID DERIVED SUPPRESSOR CELL; MYELOID LEUKEMIA; NEOPLASM; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR BLOCKING; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; SUPPRESSOR CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR IMMUNITY; TUMOR MEDIATED IMMUNOSUPPRESSION; TUMOR MICROENVIRONMENT; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASMS;

B-LYMPHOCYTES; CTLA-4 ANTIGEN; CYTOKINES; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASMS; T-LYMPHOCYTES, REGULATORY; TUMOR MICROENVIRONMENT;

EID: 84908123906     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.14.58     Document Type: Review

References (169)

1. Ehrlich P. Experimentelle Karzinomstudien an Mäusen. In: Arbeiten aus dem königlichen Institut für experimentelle Therapie zu Frankfurt a.M. Gustav Fischer, Jena, Germany, 75-102 (1906
2. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331(6024), 1565-1570 (2011
3. Wang QJ, Hanada K, Robbins PF, Li YF, Yang JC. Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinoma. Cancer Res. 72(23), 6119-6129 (2012
4. Gajewski TF, Woo SR, Zha Y et al. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr. Opin. Immunol. 25(2), 268-276 (2013
5. Sharma P, Old LJ, Allison JP. Immunotherapeutic strategies for high-risk bladder cancer. Semin. Oncol. 34(2), 165-172 (2007
6. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst. Rev. (1), CD001425 (2005
7. Kirkwood JM, Tarhini AA. Biomarkers of therapeutic response in melanoma and renal cell carcinoma: potential inroads to improved immunotherapy. J. Clin. Oncol. 27(16), 2583-2585 (2009
8. Amin A, White RL Jr High-dose interleukin-2: is it still indicated for melanoma and RCC in an era of targeted therapies?. Oncology 27(7), 680-691 (2013
9. Sabatino M, Kim-Schulze S, Panelli MC et al. Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J. Clin. Oncol. 27(16), 2645-2652 (2009
10. Grande C, Firvida JL, Navas V, Casal J. Interleukin-2 for the treatment of solid tumors other than melanoma and renal cell carcinoma. Anticancer Drugs 17(1), 1-12 (2006
11. Draube A, Klein-Gonzalez N, Mattheus S et al. Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. PLoS ONE 6(4), e18801 (2011
12. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363(5), 411-422 (2010
13. Cha E, Fong L. Immunotherapy for prostate cancer: biology and therapeutic approaches. J. Clin. Oncol. 29(27), 3677-3685 (2011
14. Higano CS, Schellhammer PF, Small EJ et al. Integrated data from 2 randomized, double-blind, placebo-controlled, Phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115(16), 3670-3679 (2009
15. Small EJ, Schellhammer PF, Higano CS et al. Placebo-controlled Phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 24(19), 3089-3094 (2006
16. Hinrichs CS, Rosenberg SA. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol. Rev. 257(1), 56-71 (2014
17. Turin I, Pedrazzoli P, Tullio C et al. GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia. Cytotherapy 9(5), 499-507 (2007
18. Marijt E, Wafelman A, Van Der Hoorn M et al. Phase I/II feasibility study evaluating the generation of leukemia-reactive cytotoxic T lymphocyte lines for treatment of patients with relapsed leukemia after allogeneic stem cell transplantation. Haematologica 92(1), 72-80 (2007
19. Rosenberg SA, Yang JC, Sherry RM et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17(13), 4550-4557 (2011
20. Mackensen A, Meidenbauer N, Vogl S, Laumer M, Berger J, Andreesen R. Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. J. Clin. Oncol. 24(31), 5060-5069 (2006
21. Kono K, Takahashi A, Ichihara F et al. Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial. Clin. Cancer Res. 8(6), 1767-1771 (2002
22. Ma C, Cheung AF, Chodon T et al. Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy. Cancer Discov. 3(4), 418-429 (2013
23. Bernhard H, Neudorfer J, Gebhard K et al. Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer. Cancer Immunol. Immunother. 57(2), 271-280 (2008
24. Comoli P, Pedrazzoli P, Maccario R et al. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J. Clin. Oncol. 23(35), 8942-8949 (2005
25. Jensen MC, Riddell SR. Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells. Immunol. Rev. 257(1), 127-144 (2014
26. Till BG, Jensen MC, Wang J et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 112(6), 2261-2271 (2008
27. Kochenderfer JN, Wilson WH, Janik JE et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116(20), 4099-4102 (2010
28. Brentjens RJ, Riviere I, Park JH et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118(18), 4817-4828 (2011
29. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365(8), 725-733 (2011
30. Grupp SA, Kalos M, Barrett D et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368(16), 1509-1518 (2013
31. Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res. 69(12), 4941-4944 (2009
32. Bargou R, Leo E, Zugmaier G et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321(5891), 974-977 (2008
33. Loffler A, Gruen M, Wuchter C et al. Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Leukemia 17(5), 900-909 (2003
34. Topp MS, Kufer P, Gokbuget N et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J. Clin. Oncol. 29(18), 2493-2498 (2011
35. Aigner M, Feulner J, Schaffer S et al. T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct. Leukemia 27(5), 1107-1115 (2013
36. Zhang P, Shi B, Gao H et al. An EpCAM/CD3 bispecific antibody efficiently eliminates hepatocellular carcinoma cells with limited galectin-1 expression. Cancer Immunol. Immunother. 63(2), 121-132 (2013
37. Groth A, Salnikov AV, Ottinger S et al. New gene-immunotherapy combining TRAIL-lymphocytes and EpCAMxCD3 bispecific antibody for tumor targeting. Clin. Cancer Res. 18(4), 1028-1038 (2012
38. Lutterbuese R, Raum T, Kischel R et al. T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS-and BRAF-mutated colorectal cancer cells. Proc. Natl Acad. Sci. USA 107(28), 12605-12610 (2010
39. Osada T, Hsu D, Hammond S et al. Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody. Br. J. Cancer 102(1), 124-133 (2010
40. Yamamoto K, Trad A, Baumgart A et al. A novel bispecific single-chain antibody for ADAM17 and CD3 induces T-cell-mediated lysis of prostate cancer cells. Biochem. J. 445(1), 135-144 (2012
41. Fortmuller K, Alt K, Gierschner D et al. Effective targeting of prostate cancer by lymphocytes redirected by a PSMA ' CD3 bispecific single-chain diabody. Prostate 71(6), 588-596 (2011
42. Galon J, Costes A, Sanchez-Cabo F et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795), 1960-1964 (2006
43. Schumacher K, Haensch W, Roefzaad C, Schlag PM. Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res. 61(10), 3932-3936 (2001
44. Fukunaga A, Miyamoto M, Cho Y et al. CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas 28(1), e26-e31 (2004
45. Sato E, Olson SH, Ahn J et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl Acad. Sci. USA 102(51), 18538-18543 (2005
46. Lee HE, Chae SW, Lee YJ et al. Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer. Br. J. Cancer 99(10), 1704-1711 (2008
47. Eiro N, Pidal I, Fernandez-Garcia B et al. Impact of CD68/(CD3+CD20) ratio at the invasive front of primary tumors on distant metastasis development in breast cancer. PLoS ONE 7(12), e52796 (2012
48. Suzuki H, Onishi H, Morisaki T, Tanaka M, Katano M. Intratumoral FOXP3(+)VEGFR2(+) regulatory T cells are predictive markers for recurrence and survival in patients with colorectal cancer (vol 146, pg 26, 2013). Clin. Immunol. 148(1), 148-148 (2013
49. Suzuki H, Chikazawa N, Tasaka T et al. Intratumoral CD8(+) T/FOXP3(+) cell ratio is a predictive marker for survival in patients with colorectal cancer. Cancer Immunol. Immun. 59(5), 653-661 (2010
50. Whiteside TL. What are regulatory T cells (Treg) regulating in cancer and why?. Semin. Cancer Biol. 22(4), 327-334 (2012
51. Van Maren WW, Jacobs JF, De Vries IJ, Nierkens S, Adema GJ. Toll-like receptor signalling on Tregs: to suppress or not to suppress?. Immunology 124(4), 445-452 (2008
52. Menetrier-Caux C, Curiel T, Faget J, Manuel M, Caux C, Zou W. Targeting regulatory T cells. Target Oncol. 7(1), 15-28 (2012
53. Bos PD, Plitas G, Rudra D, Lee SY, Rudensky AY. Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy. J. Exp. Med. 210(11), 2435-2466 (2013
54. Klages K, Mayer CT, Lahl K et al. Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma. Cancer Res. 70(20), 7788-7799 (2010
55. Li X, Kostareli E, Suffner J, Garbi N, Hammerling GJ. Efficient Treg depletion induces T-cell infiltration and rejection of large tumors. Eur. J. Immunol. 40(12), 3325-3335 (2010
56. Teng MW, Ngiow SF, Von Scheidt B, McLaughlin N, Sparwasser T, Smyth MJ. Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth. Cancer Res. 70(20), 7800-7809 (2010
57. Okita R, Yamaguchi Y, Ohara M et al. Targeting of CD4+CD25high cells while preserving CD4+CD25low cells with low-dose chimeric anti-CD25 antibody in adoptive immunotherapy of cancer. Int. J. Oncol. 34(2), 563-572 (2009
58. Vondran FW, Timrott K, Tross J et al. Impact of basiliximab on regulatory T-cells early after kidney transplantation: down-regulation of CD25 by receptor modulation. Transpl. Int. 23(5), 514-523 (2010
59. Rech AJ, Mick R, Martin S et al. CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients. Sci. Transl. Med. 4(134), 134ra162 (2012
60. Morse MA, Hobeika AC, Osada T et al. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 112(3), 610-618 (2008
61. Dannull J, Su Z, Rizzieri D et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. 115(12), 3623-3633 (2005
62. Jacobs JF, Punt CJ, Lesterhuis WJ et al. Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a Phase I/II study in metastatic melanoma patients. Clin. Cancer Res. 16(20), 5067-5078 (2010
63. Gagliani N, Magnani CF, Huber S et al. Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nat. Med. 19(6), 739-746 (2013
64. Bastid J, Cottalorda-Regairaz A, Alberici G, Bonnefoy N, Eliaou JF, Bensussan A. ENTPD1/CD39 is a promising therapeutic target in oncology. Oncogene 32(14), 1743-1751 (2013
65. Mandapathil M, Lang S, Gorelik E, Whiteside TL. Isolation of functional human regulatory T cells (Treg) from the peripheral blood based on the CD39 expression. J. Immunol. Methods 346(1-2), 55-63 (2009
66. Croft M. Control of immunity by the TNFR-related molecule OX40 (CD134). Annu. Rev. Immunol. 28, 57-78 (2010
67. Weinberg AD, Morris NP, Kovacsovics-Bankowski M, Urba WJ, Curti BD. Science gone translational: the OX40 agonist story. Immunol. Rev. 244(1), 218-231 (2011
68. Weinberg AD, Rivera MM, Prell R et al. Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J. Immunol. 164(4), 2160-2169 (2000
69. Pardee AD, McCurry D, Alber S, Hu P, Epstein AL, Storkus WJ. A therapeutic OX40 agonist dynamically alters dendritic, endothelial, and T cell subsets within the established tumor microenvironment. Cancer Res. 70(22), 9041-9052 (2010
70. Curti BD, Kovacsovics-Bankowski M, Morris N et al. OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res. 73(24), 7189-7198 (2013
71. Melero I, Shuford WW, Newby SA et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat. Med. 3(6), 682-685 (1997
72. Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME, Sakaguchi S, Houghton AN. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J. Exp. Med. 200(6), 771-782 (2004
73. Stephens GL, McHugh RS, Whitters MJ et al. Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4+CD25+ T cells. J. Immunol. 173(8), 5008-5020 (2004
74. Moran AE, Kovacsovics-Bankowski M, Weinberg AD. The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy. Curr. Opin. Immunol. 25(2), 230-237 (2013
75. Clinical trials registry. http://clinicaltrials.gov
76. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364(26), 2517-2526 (2011
77. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010
78. Walker LS, Sansom DM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat. Rev. Immunol. 11(12), 852-863 (2011
79. Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J. Clin. Invest. 116(7), 1935-1945 (2006
80. Liakou CI, Kamat A, Tang DN et al. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc. Natl Acad. Sci. USA 105(39), 14987-14992 (2008
81. Chen H, Liakou CI, Kamat A et al. Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proc. Natl Acad. Sci. USA 106(8), 2729-2734 (2009
82. Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res. 73(12), 3591-3603 (2013
83. Wang CJ, Kenefeck R, Wardzinski L et al. Cutting edge: cell-extrinsic immune regulation by CTLA-4 expressed on conventional T cells. J. Immunol. 189(3), 1118-1122 (2012
84. Qureshi OS, Zheng Y, Nakamura K et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 332(6029), 600-603 (2011
85. Simpson TR, Li F, Montalvo-Ortiz W et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med. 210(9), 1695-1710 (2013
86. Ma C, Zhang Q, Ye J et al. Tumor-infiltrating gammadelta T lymphocytes predict clinical outcome in human breast cancer. J. Immunol. 189(10), 5029-5036 (2012
87. Iliopoulou EG, Karamouzis MV, Missitzis I et al. Increased frequency of CD4+ cells expressing CD161 in cancer patients. Clin. Cancer Res. 12(23), 6901-6909 (2006
88. Nelson BH. CD20+ B cells: the other tumor-infiltrating lymphocytes. J. Immunol. 185(9), 4977-4982 (2010
89. Catellani S, Pierri I, Gobbi M, Poggi A, Zocchi MR. Imatinib treatment induces CD5+ B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemia. PLoS ONE 6(4), e18925 (2011
90. Jahrsdorfer B, Blackwell SE, Wooldridge JE et al. B-chronic lymphocytic leukemia cells and other B cells can produce granzyme B and gain cytotoxic potential after interleukin-21-based activation. Blood 108(8), 2712-2719 (2006
91. Dilillo DJ, Yanaba K, Tedder TF. B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice. J. Immunol. 184(7), 4006-4016 (2010
92. Iwata Y, Matsushita T, Horikawa M et al. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 117(2), 530-541 (2011
93. Ammirante M, Luo JL, Grivennikov S, Nedospasov S, Karin M. B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature 464(7286), 302-305 (2010
94. Flores-Borja F, Bosma A, Ng D et al. CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation. Sci. Transl. Med. 5(173), 173ra123 (2013
95. Sorrentino R, Morello S, Forte G et al. B cells contribute to the antitumor activity of CpG-oligodeoxynucleotide in a mouse model of metastatic lung carcinoma. Am. J. Respir. Crit. Care Med. 183(10), 1369-1379 (2011
96. Olkhanud PB, Damdinsuren B, Bodogai M et al. Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4(+) T cells to T-regulatory cells. Cancer Res. 71(10), 3505-3515 (2011
97. Nielsen JS, Sahota RA, Milne K et al. CD20+ tumor-infiltrating lymphocytes have an atypical CD27-memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. Clin. Cancer Res. 18(12), 3281-3292 (2012
98. Schmidt M, Micke P, Hengstler JG. IGKC and prognosis in breast cancer. Clin. Cancer Res. 19(1), 304 (2013
99. Bindea G, Mlecnik B, Tosolini M et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39(4), 782-795 (2013
100. Andreu P, Johansson M, Affara NI et al. FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell 17(2), 121-134 (2010
101. Schmidt M, Hellwig B, Hammad S et al. A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin kappa C as a compatible prognostic marker in human solid tumors. Clin. Cancer Res. 18(9), 2695-2703 (2012
102. Carpenter EL, Mick R, Rech AJ et al. Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers. Clin. Cancer Res. 15(13), 4277-4287 (2009
103. Zirakzadeh AA, Marits P, Sherif A, Winqvist O. Multiplex B cell characterization in blood, lymph nodes, and tumors from patients with malignancies. J. Immunol. 190(11), 5847-5855 (2013
104. Lindner S, Dahlke K, Sontheimer K et al. Interleukin 21-induced granzyme B-expressing B cells infiltrate tumors and regulate T cells. Cancer Res. 73(8), 2468-2479 (2013
105. Lindau D, Gielen P, Kroesen M, Wesseling P, Adema GJ. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology 138(2), 105-115 (2013
106. Najjar YG, Finke JH. Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer. Front. Oncol. 3, 49 (2013
107. Jordan KR, Amaria RN, Ramirez O et al. Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients. Cancer Immunol. Immunother. 62(11), 1711-1722 (2013
108. Zhang B, Wang Z, Wu L et al. Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma. PLoS ONE 8(2), e57114 (2013
109. Arihara F, Mizukoshi E, Kitahara M et al. Increase in CD14+HLA-DR -/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis. Cancer Immunol. Immunother. 62(8), 1421-1430 (2013
110. Lee JM, Seo JH, Kim YJ, Kim YS, Ko HJ, Kang CY. The restoration of myeloid-derived suppressor cells as functional antigen-presenting cells by NKT cell help and all-trans-retinoic acid treatment. Int. J. Cancer 131(3), 741-751 (2012
111. Kusmartsev S, Su Z, Heiser A et al. Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin. Cancer Res. 14(24), 8270-8278 (2008
112. Kusmartsev S, Cheng F, Yu B et al. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res. 63(15), 4441-4449 (2003
113. Obermajer N, Muthuswamy R, Odunsi K, Edwards RP, Kalinski P. PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res. 71(24), 7463-7470 (2011
114. Umansky V, Sevko A. Overcoming immunosuppression in the melanoma microenvironment induced by chronic inflammation. Cancer Immunol. Immunother. 61(2), 275-282 (2012
115. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat. Immunol. 8(3), 239-245 (2007
116. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12(4), 252-264 (2012
117. Titanji K, Velu V, Chennareddi L et al. Acute depletion of activated memory B cells involves the PD-1 pathway in rapidly progressing SIV-infected macaques. J. Clin. Invest. 120(11), 3878-3890 (2010
118. Terme M, Ullrich E, Aymeric L et al. IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res. 71(16), 5393-5399 (2011
119. Benson DM Jr, Bakan CE, Mishra A et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 116(13), 2286-2294 (2010
120. Thompson RH, Kuntz SM, Leibovich BC et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 66(7), 3381-3385 (2006
121. Hamanishi J, Mandai M, Iwasaki M et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc. Natl Acad. Sci. USA 104(9), 3360-3365 (2007
122. Wu C, Zhu Y, Jiang J, Zhao J, Zhang XG, Xu N. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem. 108(1), 19-24 (2006
123. Ohigashi Y, Sho M, Yamada Y et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin. Cancer Res. 11(8), 2947-2953 (2005
124. Krambeck AE, Dong H, Thompson RH et al. Survivin and b7-h1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma. Clin. Cancer Res. 13(6), 1749-1756 (2007
125. Gao Q, Wang XY, Qiu SJ et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin. Cancer Res. 15(3), 971-979 (2009
126. Zhang L, Gajewski TF, Kline J. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood 114(8), 1545-1552 (2009
127. Dong H, Strome SE, Salomao DR et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8(8), 793-800 (2002
128. Blank C, Kuball J, Voelkl S et al. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int. J. Cancer 119(2), 317-327 (2006
129. Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366(26), 2455-2465 (2012
130. Hodi FS, Powles T, Cassier P et al. MPDL3280A (anti-PDL1): clinical activity, safety and biomarkers of an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors. Eur. J. Cancer 49, S184-S184 (2013
131. Brahmer JR, Drake CG, Wollner I et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28(19), 3167-3175 (2010
132. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443-2454 (2012
133. Wolchok JD, Kluger H, Callahan MK et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369(2), 122-133 (2013
134. Weber JS, Kudchadkar RR, Yu B et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J. Clin. Oncol. 31(34), 4311-4318 (2013
135. Berger R, Rotem-Yehudar R, Slama G et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin. Cancer Res. 14(10), 3044-3051 (2008
136. Armand P, Nagler A, Weller EA et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international Phase II trial. J. Clin. Oncol. 31(33), 4199-4206 (2013
137. Westin JR, Chu F, Zhang M et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, Phase 2 trial. Lancet Oncol. 15(1), 69-77 (2014
138. Hamid O, Robert C, Daud A et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369(2), 134-144 (2013
139. Salvi S, Fontana V, Boccardo S et al. Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer. Cancer Immunol. Immunother. 61(9), 1463-1472 (2012
140. Mao H, Zhang L, Yang Y et al. New insights of CTLA-4 into its biological function in breast cancer. Curr. Cancer Drug Targets 10(7), 728-736 (2010
141. Contardi E, Palmisano GL, Tazzari PL et al. CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. Int. J. Cancer 117(4), 538-550 (2005
142. Godin-Ethier J, Hanafi LA, Piccirillo CA, Lapointe R. Indoleamine 2, 3-dioxygenase expression in human cancers: clinical and immunologic perspectives. Clin. Cancer Res. 17(22), 6985-6991 (2011
143. Brandacher G, Perathoner A, Ladurner R et al. Prognostic value of indoleamine 2, 3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin. Cancer Res. 12(4), 1144-1151 (2006
144. Ye J, Liu H, Hu Y, Li P, Zhang G, Li Y. Tumoral indoleamine 2, 3-dioxygenase expression predicts poor outcome in laryngeal squamous cell carcinoma. Virchows Arch. 462(1), 73-81 (2013
145. Wainwright DA, Balyasnikova IV, Chang AL et al. IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin. Cancer Res. 18(22), 6110-6121 (2012
146. Speeckaert R, Vermaelen K, Van Geel N et al. Indoleamine 2, 3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients. Eur. J. Cancer 48(13), 2004-2011 (2012
147. Suzuki Y, Suda T, Furuhashi K et al. Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer. Lung Cancer 67(3), 361-365 (2010
148. Wang D, Saga Y, Mizukami H et al. Indoleamine-2, 3-dioxygenase, an immunosuppressive enzyme that inhibits natural killer cell function, as a useful target for ovarian cancer therapy. Int. J. Oncol. 40(4), 929-934 (2012
149. Liu X, Shin N, Koblish HK et al. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood 115(17), 3520-3530 (2010
150. Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol. 14(6), e218-e228 (2013
151. Stevenson JP, Kindler HL, Papasavvas E et al. Immunological effects of the TGFbeta-blocking antibody GC1008 in malignant pleural mesothelioma patients. Oncoimmunology 2(8), e26218 (2013
152. Nagaraj NS, Datta PK. Targeting the transforming growth factor-beta signaling pathway in human cancer. Expert Opin. Investig. Drugs 19(1), 77-91 (2010
153. Carretero R, Wang E, Rodriguez AI et al. Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes. Int. J. Cancer 131(2), 387-395 (2012
154. Kitamura H, Honma I, Torigoe T, Asanuma H, Sato N, Tsukamoto T. Down-regulation of HLA class I antigen is an independent prognostic factor for clear cell renal cell carcinoma. J. Urol. 177(4), 1269-1272 (2007
155. Bandoh N, Ogino T, Katayama A et al. HLA class I antigen and transporter associated with antigen processing downregulation in metastatic lesions of head and neck squamous cell carcinoma as a marker of poor prognosis. Oncol. Rep. 23(4), 933-939 (2010
156. Seliger B, Atkins D, Bock M et al. Characterization of human lymphocyte antigen class I antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter-associated with antigen-processing down-regulation. Clin. Cancer Res. 9(5), 1721-1727 (2003
157. Kasajima A, Sers C, Sasano H et al. Down-regulation of the antigen processing machinery is linked to a loss of inflammatory response in colorectal cancer. Hum. Pathol. 41(12), 1758-1769 (2010
158. Liu Q, Hao C, Su P, Shi J. Down-regulation of HLA class I antigen-processing machinery components in esophageal squamous cell carcinomas: association with disease progression. Scand. J. Gastroenterol. 44(8), 960-969 (2009
159. Cresswell AC, Sisley K, Laws D, Parsons MA, Rennie IG, Murray AK. Reduced expression of TAP-1 and TAP-2 in posterior uveal melanoma is associated with progression to metastatic disease. Melanoma Res. 11(3), 275-281 (2001
160. Seliger B, Stoehr R, Handke D et al. Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer. Cancer Immunol. Immunother. 59(4), 529-540 (2010
161. Vitale M, Pelusi G, Taroni B et al. HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage. Clin. Cancer Res. 11(1), 67-72 (2005
162. Atkins D, Ferrone S, Schmahl GE, Storkel S, Seliger B Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma?. J. Urol. 171(2 Pt 1), 885-889 (2004
163. Han LY, Fletcher MS, Urbauer DL et al. HLA class I antigen processing machinery component expression and intratumoral T-cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin. Cancer Res. 14(11), 3372-3379 (2008
164. Kamarashev J, Ferrone S, Seifert B et al. TAP1 down-regulation in primary melanoma lesions: an independent marker of poor prognosis. Int. J. Cancer 95(1), 23-28 (2001
165. Mimura K, Shiraishi K, Mueller A et al. The MAPK pathway is a predominant regulator of HLA-A expression in esophageal and gastric cancer. J. Immunol. 191(12), 6261-6272 (2013
166. Yuan J, Adamow M, Ginsberg BA et al. Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc. Natl Acad. Sci. USA 108(40), 16723-16728 (2011
167. Marabelle A, Kohrt H, Sagiv-Barfi I et al. Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J. Clin. Invest. 123(6), 2447-2463 (2013
168. Deng L, Liang H, Burnette B et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J. Clin. Invest. 124(2), 687-695 (2014
169. Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP. Indoleamine 2, 3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J. Exp. Med. 210(7), 1389-1402 (2013